# Isomorphic Labs Moves AlphaFold 3-Designed Drugs Into Phase I Human Trials

> Isomorphic Labs, the DeepMind drug-discovery spinout, is moving its first fully AI-designed drug candidates toward Phase I human trials, with the company now targeting the end of 2026 to put molecules into people. The pipeline is built on AlphaFold 3, the protein-structure model that lets researchers design and screen candidate compounds on a computer before any lab bench work begins. The headline claim is speed. Isomorphic says its preclinical stage, the years of design and testing that precede human trials, has been squeezed from a typical five to seven years down to roughly 24 to 30 months. Early programs focus on oncology and immunology, two areas where better-targeted molecules could matter most. The caveat worth keeping in mind is that reaching Phase I is the start of the hard part, not the finish. Most drugs that enter human testing still fail on safety or efficacy, and AI design does nothing to change trial biology. Still, if the compression holds, it hints at a future where the slow, expensive front end of drug discovery looks very different.

_Section: [Daily AI Updates](https://www.wortins.com/daily-ai) · Source: IntuitionLabs · Published Monday, August 17, 2026_

## Wortins' read

Isomorphic Labs, the DeepMind drug-discovery spinout, is moving its first fully AI-designed drug candidates toward Phase I human trials, with the company now targeting the end of 2026 to put molecules into people. The pipeline is built on AlphaFold 3, the protein-structure model that lets researchers design and screen candidate compounds on a computer before any lab bench work begins. The headline claim is speed. Isomorphic says its preclinical stage, the years of design and testing that precede human trials, has been squeezed from a typical five to seven years down to roughly 24 to 30 months. Early programs focus on oncology and immunology, two areas where better-targeted molecules could matter most. The caveat worth keeping in mind is that reaching Phase I is the start of the hard part, not the finish. Most drugs that enter human testing still fail on safety or efficacy, and AI design does nothing to change trial biology. Still, if the compression holds, it hints at a future where the slow, expensive front end of drug discovery looks very different.

## Source

[Read the full story at IntuitionLabs](https://intuitionlabs.ai/articles/isomorphic-labs-alphafold-ai-drug-discovery-trials)

## Related coverage

- [Emerald AI Raises $150 Million Series A at $1.05 Billion Valuation](https://www.wortins.com/story/emerald-ai-raises-150-million-series-a-at-1-05-billion-valua-2071899e) — [Business Wire](https://www.businesswire.com/news/home/20260825127649/en/Emerald-AI-Raises-$150-Million-Series-A-at-$1.05-Billion-Valuation-to-Scale-Power-Flexible-AI-Data-Centers)
- [Google Cloud Launches Gemini Enterprise for Financial Services](https://www.wortins.com/story/google-cloud-launches-gemini-enterprise-for-financial-servic-5d0fd141) — [Google Cloud](https://www.googlecloudpresscorner.com/2026-08-25-Google-Cloud-Launches-Gemini-Enterprise-for-Financial-Services)
- [Apple Updates, AI Computers, and OpenAI's Jalapeño Chip](https://www.wortins.com/story/apple-updates-ai-computers-and-openai-s-jalape-o-chip-adb3115c) — [Stratechery](https://stratechery.com/2026/apple-updates-mini-and-studio-ai-computers-openai-jalapeno/)
- [Anthropic Adds Claude Mythos 5 to Claude Security for Vulnerability Scanning](https://www.wortins.com/story/anthropic-adds-claude-mythos-5-to-claude-security-for-vulner-34ff7302) — [Anthropic](https://claude.com/blog/bringing-claude-mythos-5-to-more-defenders)
- [Callosum Raises $100 Million to Match AI Tasks with Most Cost-Effective Models](https://www.wortins.com/story/callosum-raises-100-million-to-match-ai-tasks-with-most-cost-da05cef6) — [Bloomberg](https://www.bloomberg.com/news/articles/2026-08-20/ai-startup-callosum-raises-100-million-to-make-ai-tasks-cheaper)
- [Transfyr Raises $25 Million Seed for Physical AI Platform](https://www.wortins.com/story/transfyr-raises-25-million-seed-for-physical-ai-platform-163dfbba) — [TechStartups](https://techstartups.com/2026/08/26/startup-funding-news-today-august-26-2026-emerald-ai-gatik-stellaria-more/)

---

_Curated and written by [Wortins](https://www.wortins.com) — The daily AI briefing. Every story links to its original source; the "Wortins read" on each is our own original analysis. [About Wortins & our editorial approach](https://www.wortins.com/about)._